- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03806036
The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovary
January 13, 2019 updated by: Ahmed Maged, Cairo University
The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovarian Syndrome
The study included 100 female diagnosed with polycystic ovary syndrome.
They were classified into 2 groups: Study group included 50 women will receive 300.000 I.U single dose of Vitamin D intramuscular injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day .
Control group included 50 women will receive only clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day.
Serum 25 hydroxy Vitamin D3, Serum Leptin and FSH will be done to all women before and after intervention.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study included 100 female diagnosed with polycystic ovary syndrome diagnosed by by presence of 2 out of 3 criteria (according to ESHRE/ASRM in Rotterdam in 2003): oligoovulation and/or an ovulation , excess androgen activity (clinical or biochemical) and polycystic ovaries (by pelvic ultrasound "vaginal route").They were classified into 2 groups: Study group included 50 women will receive 300.000 I.U single dose of Vitamin D intramuscular injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day .
Control group included 50 women will receive only clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day.
Serum 25 hydroxy Vitamin D3, Serum Leptin and FSH will be done to all women before and after intervention.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ahmed Maged, MD
- Phone Number: +201005227404
- Email: prof.ahmedmaged@gmail.com
Study Contact Backup
- Name: Wesam Deeb, MD
- Email: wessamdeeb74@gmail.com
Study Locations
-
-
-
Cairo, Egypt, 12151
- Recruiting
- Kasr Alainy medical school
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
1- BMI: more than 25.0 kg/m2
2- PCO was diagnosed by presence of 2 out of 3 criteria (according to ESHRE/ASRM in Rotterdam in 2003)
- oligoovulation and/or an ovulation
- excess androgen activity (clinical or biochemical)
- polycystic ovaries (by pelvic ultrasound "vaginal route")
3- Anovulatory patient resistant to induction with clomiphene citrate alone
Exclusion Criteria:
-1) BMI: more than 35.0 kg/m2
2) Infertile women due to any factor other than PCO
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vitamin D group
50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
|
300.000 I.U single dose of VIT D IM injection
100mg daily for 5 days starting from third day of menstruation
Other Names:
|
Placebo Comparator: Control group
50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
|
100mg daily for 5 days starting from third day of menstruation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ovulation
Time Frame: 14 days after menses
|
appearance of dominant follicle 18 - 22 mm in diameter
|
14 days after menses
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2018
Primary Completion (Anticipated)
February 1, 2019
Study Completion (Anticipated)
February 1, 2019
Study Registration Dates
First Submitted
January 13, 2019
First Submitted That Met QC Criteria
January 13, 2019
First Posted (Actual)
January 16, 2019
Study Record Updates
Last Update Posted (Actual)
January 16, 2019
Last Update Submitted That Met QC Criteria
January 13, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Syndrome
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Micronutrients
- Hormone Antagonists
- Vitamins
- Bone Density Conservation Agents
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Vitamin D
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- 47 (Other Identifier: IASO Thessalias)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovary Syndrome
-
Cairo UniversityCompleted
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark
-
Odense University HospitalCompleted
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Assaf-Harofeh Medical CenterUnknownInfertility | Polycystic OvariesIsrael
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedPolycystic Ovary Syndrome (PCOS)United States
Clinical Trials on Vitamin D
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Khon Kaen UniversityNot yet recruiting
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
University Hospital, Basel, SwitzerlandCompleted
-
Cornell UniversityArogyavaram Medical CentreNot yet recruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting